JOHNSON KIMBERLY H
Known title: COO and VPCIK: 0001658089
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Transaction History
| TROW | ▲ Buy | Grant | 244 | $24K | 12/10/2025 | View on chart |
| TROW | ▼ Sell | Tax Withholding | 2,855 | $301K | 12/10/2025 | View on chart |
| LLY | ▲ Buy | Grant | 215 | $220K | 11/17/2025 | View on chart |
| TROW | ▼ Sell | Tax Withholding | 600 | $53K | 5/2/2025 | View on chart |
| TROW | ▲ Buy | Grant | 186 | $19K | 5/2/2025 | View on chart |
| LLY | ▲ Buy | Grant | 12 | $10K | 12/16/2024 | View on chart |
| TROW | ▼ Sell | Tax Withholding | 1,617 | $200K | 12/10/2024 | View on chart |
| TROW | ▲ Buy | Grant | 15,448 | $0 | 12/4/2024 | View on chart |
| TROW | ▲ Buy | Grant | 213 | $24K | 12/4/2024 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $10K | 11/18/2024 | View on chart |
| LLY | ▲ Buy | Grant | 303 | $220K | 11/18/2024 | View on chart |
| LLY | ▲ Buy | Grant | 11 | $10K | 10/21/2024 | View on chart |
| LLY | ▲ Buy | Grant | 10 | $9K | 9/16/2024 | View on chart |
| LLY | ▲ Buy | Grant | 10 | $9K | 8/19/2024 | View on chart |
| LLY | ▲ Buy | Grant | 10 | $10K | 7/15/2024 | View on chart |
| LLY | ▲ Buy | Grant | 11 | $10K | 6/17/2024 | View on chart |
| LLY | ▲ Buy | Grant | 12 | $9K | 5/20/2024 | View on chart |
| TROW | ▼ Sell | Tax Withholding | 601 | $66K | 5/2/2024 | View on chart |
| TROW | ▲ Buy | Grant | 164 | $18K | 5/2/2024 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $10K | 4/15/2024 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $10K | 3/18/2024 | View on chart |
| LLY | ▲ Buy | Grant | 13 | $10K | 2/20/2024 | View on chart |
| LLY | ▲ Buy | Grant | 15 | $10K | 1/16/2024 | View on chart |
| LLY | ▲ Buy | Grant | 17 | $10K | 12/18/2023 | View on chart |
| TROW | ▼ Sell | Tax Withholding | 596 | $60K | 12/8/2023 | View on chart |
| TROW | ▲ Buy | Grant | 216 | $23K | 12/5/2023 | View on chart |
| TROW | ▲ Buy | Grant | 16,908 | $0 | 12/5/2023 | View on chart |
| LLY | ▲ Buy | Grant | 16 | $10K | 11/20/2023 | View on chart |
| LLY | ▲ Buy | Grant | 335 | $200K | 11/20/2023 | View on chart |
| LLY | ▲ Buy | Grant | 16 | $10K | 10/16/2023 | View on chart |
| LLY | ▲ Buy | Grant | 17 | $10K | 9/18/2023 | View on chart |
| LLY | ▲ Buy | Grant | 18 | $10K | 8/21/2023 | View on chart |
| LLY | ▲ Buy | Grant | 22 | $10K | 7/17/2023 | View on chart |
| LLY | ▲ Buy | Grant | 21 | $9K | 6/20/2023 | View on chart |
| LLY | ▲ Buy | Grant | 22 | $10K | 5/15/2023 | View on chart |
| TROW | ▼ Sell | Tax Withholding | 607 | $68K | 5/2/2023 | View on chart |
| TROW | ▲ Buy | Grant | 155 | $17K | 5/2/2023 | View on chart |
| LLY | ▲ Buy | Grant | 26 | $10K | 4/17/2023 | View on chart |
| LLY | ▲ Buy | Grant | 29 | $10K | 3/20/2023 | View on chart |
| LLY | ▲ Buy | Grant | 30 | $10K | 2/21/2023 | View on chart |
| LLY | ▲ Buy | Grant | 27 | $10K | 1/17/2023 | View on chart |
| LLY | ▲ Buy | Grant | 27 | $10K | 12/19/2022 | View on chart |
| TROW | ▲ Buy | Grant | 9,891 | $0 | 12/6/2022 | View on chart |
| TROW | ▲ Buy | Grant | 210 | $25K | 12/6/2022 | View on chart |
| LLY | ▲ Buy | Grant | 27 | $10K | 11/21/2022 | View on chart |
| LLY | ▲ Buy | Grant | 498 | $180K | 11/21/2022 | View on chart |
| LLY | ▲ Buy | Grant | 29 | $10K | 10/17/2022 | View on chart |
| LLY | ▲ Buy | Grant | 32 | $10K | 9/19/2022 | View on chart |
| LLY | ▲ Buy | Grant | 31 | $10K | 8/15/2022 | View on chart |
| LLY | ▲ Buy | Grant | 30 | $10K | 7/18/2022 | View on chart |
| LLY | ▲ Buy | Grant | 33 | $10K | 6/21/2022 | View on chart |
| LLY | ▲ Buy | Grant | 32 | $10K | 5/16/2022 | View on chart |
| TROW | ▲ Buy | Grant | 9,978 | $0 | 5/2/2022 | View on chart |
| LLY | ▲ Buy | Grant | 32 | $10K | 4/18/2022 | View on chart |
| LLY | ▲ Buy | Grant | 33 | $10K | 3/21/2022 | View on chart |
| LLY | ▲ Buy | Grant | 40 | $10K | 2/22/2022 | View on chart |
| LLY | ▲ Buy | Grant | 39 | $10K | 1/18/2022 | View on chart |
| LLY | ▲ Buy | Grant | 37 | $10K | 12/20/2021 | View on chart |
| LLY | ▲ Buy | Grant | 37 | $10K | 11/15/2021 | View on chart |
| LLY | ▲ Buy | Grant | 621 | $160K | 11/15/2021 | View on chart |
| LLY | ▲ Buy | Grant | 40 | $10K | 10/18/2021 | View on chart |
| LLY | ▲ Buy | Grant | 42 | $0 | 9/20/2021 | View on chart |
| LLY | ▲ Buy | Grant | 36 | $10K | 8/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
T. Rowe Price Faces Advisor Hiring Push and Dividend Debate
T. Rowe Price is testing its growth strategy with a new advisor hiring push, while analysts note a modest fair‑value cut amid mixed views. The firm’s dividend yield of 4.97% keeps it in the conversation with other dividend leaders, and a recent 38% share drop has led some to label it undervalued. Earnings expectations are being watched closely as the company prepares its next quarterly report.
T. Rowe Price Faces Advisor Hiring Push and Dividend Debate. T. Rowe Price is testing its growth strategy with a new advisor hiring push, while analysts note a modest fair‑value cut amid mixed views. The firm’s dividend yield of 4.97% keeps it in the conversation with other dividend leaders, and a recent 38% share drop has led some to label it undervalued. Earnings expectations are being watched closely as the company prepares its next quarterly report.